Assess whether RWE can replace or only supplement an RCT (3a52ca)

Situation

In an RWE group proposing a post-marketing study instead of a new RCT, RWE protocol that may not meet regulator expectations is the evidence after a CRL citing manufacturing, not efficacy. Labeling negotiator has to pick RWE can replace or Only supplement an RCT for this Pharma & Life Sciences Clinical and Evidence Strategy close using RWE protocol that may not meet regulator expectations.

Decision

Labeling negotiator in an RWE group proposing a post-marketing study instead of a new RCT must choose RWE can replace / Only supplement an RCT using RWE protocol that may not meet regulator expectations after a CRL citing manufacturing, not efficacy.

Hypotheses to test

• Labeling negotiator can defend RWE can replace from RWE protocol that may not meet regulator expectations after a CRL citing manufacturing, not efficacy in a Pharma & Life Sciences challenge.
• Labeling negotiator cannot defend RWE can replace from RWE protocol that may not meet regulator expectations; Only supplement an RCT is what the extract actually supports after a CRL citing manufacturing, not efficacy.
• A CRL citing manufacturing, not efficacy never reached the population in RWE protocol that may not meet regulator expectations — reopen intake, do not close RWE can replace or.
• Two facts in RWE protocol that may not meet regulator expectations after a CRL citing manufacturing, not efficacy conflict for labeling negotiator; hold this Clinical and Evidence Strategy file.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on RWE can replace or.
• Check whether RWE protocol that may not meet regulator expectations supports the labeled claim labeling negotiator would keep.
• Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read RWE protocol that may not meet regulator expectations against a CRL citing manufacturing, not efficacy and write the one fact that would move RWE can replace or for labeling negotiator.

Recommendation

Choose RWE can replace / Only supplement an RCT on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (RWE protocol that may not meet regulator expectations after a CRL citing manufacturing, not efficacy). The follow-on Clinical and Evidence Strategy action is what labeling negotiator does next: implement the option, assign an owner, and log the missing fact.